

Osamu Matsuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7088103/publications.pdf>

Version: 2024-02-01

147
papers

2,783
citations

218677

26
h-index

233421

45
g-index

149
all docs

149
docs citations

149
times ranked

3020
citing authors

#	ARTICLE	IF	CITATIONS
1	Î±2-antiplasmin positively regulates endothelial-to-mesenchymal transition and fibrosis progression in diabetic nephropathy. <i>Molecular Biology Reports</i> , 2022, 49, 205-215.	2.3	8
2	Role of Macrophages and Plasminogen Activator Inhibitor-1 in Delayed Bone Repair Induced by Glucocorticoids in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 478.	4.1	3
3	Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, .	1.3	3
4	Role of plasminogen activator inhibitor-1 in muscle wasting induced by a diabetic state in female mice. <i>Endocrine Journal</i> , 2021, 68, 1421-1428.	1.6	1
5	Î±2-Antiplasmin as a potential regulator of the spatial memory process and age-related cognitive decline. <i>Molecular Brain</i> , 2020, 13, 140.	2.6	2
6	Î±2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 267-278.	2.7	14
7	PAI-1 is involved in delayed bone repair induced by glucocorticoids in mice. <i>Bone</i> , 2020, 134, 115310.	2.9	11
8	Short-term inhibition of fibrinolytic system restores locomotor function after spinal cord injury in mice. <i>Scientific Reports</i> , 2019, 9, 16024.	3.3	4
9	Plasminogen activator inhibitor-1 is involved in interleukin-1Î²-induced matrix metalloproteinase expression in murine chondrocytes. <i>Modern Rheumatology</i> , 2019, 29, 959-963.	1.8	3
10	Plasminogen activator inhibitor-1 deficiency suppresses osteoblastic differentiation of mesenchymal stem cells in mice. <i>Journal of Cellular Physiology</i> , 2019, 234, 9687-9697.	4.1	17
11	Role of Macrophages and Plasminogen Activator Inhibitor-1 in Delayed Bone Repair in Diabetic Female Mice. <i>Endocrinology</i> , 2018, 159, 1875-1885.	2.8	15
12	Role of plasminogen activator inhibitor-1 in glucocorticoid-induced muscle change in mice. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 148-156.	2.7	18
13	Roles of plasminogen in the alterations in bone marrow hematopoietic stem cells during bone repair. <i>Bone Reports</i> , 2018, 8, 195-203.	0.4	4
14	A synthetic peptide derived from staphylokinase enhances FGF-2-induced skin wound healing in mice. <i>Thrombosis Research</i> , 2017, 157, 7-8.	1.7	2
15	Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 1018-1027.	1.7	7
16	Plasminogen activator inhibitor-1 deficiency enhances subchondral osteopenia after induction of osteoarthritis in mice. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 392.	1.9	12
17	Î±2-antiplasmin modulates bone formation by negatively regulating osteoblast differentiation and function. <i>International Journal of Molecular Medicine</i> , 2017, 40, 854-858.	4.0	8
18	uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca ²⁺ /CaMKK/AMPK Axis. <i>International Journal of Biological Sciences</i> , 2016, 12, 63-71.	6.4	41

#	ARTICLE	IF	CITATIONS
19	The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin α 2 β 3/Akt pathway. <i>Immunity, Inflammation and Disease</i> , 2016, 4, 338-349.	2.7	15
20	Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity. <i>Diabetes Research and Clinical Practice</i> , 2016, 120, 190-193.	2.8	8
21	Evaluation of antithrombotic effect: Importance of testing components and methodologies. <i>Drug Discoveries and Therapeutics</i> , 2015, 9, 258-266.	1.5	7
22	The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice. <i>PLoS ONE</i> , 2015, 10, e0123982.	2.5	22
23	Tissue plasminogen activator modulates emotion in a social context. <i>Behavioural Brain Research</i> , 2015, 281, 24-31.	2.2	9
24	Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice. <i>Diabetes</i> , 2015, 64, 2194-2206.	0.6	55
25	α 2-Antiplasmin is involved in bone loss induced by ovariectomy in mice. <i>Bone</i> , 2015, 79, 233-241.	2.9	15
26	Role of plasminogen activator inhibitor-1 in the pathogenesis of bone metabolism abnormalities. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2015, 26, 619-625.	0.1	0
27	Plasminogen Activator Inhibitor-1 Is Involved in Impaired Bone Repair Associated with Diabetes in Female Mice. <i>PLoS ONE</i> , 2014, 9, e92686.	2.5	46
28	Altered Behavior in Mice with Deletion of the Alpha2-Antiplasmin Gene. <i>PLoS ONE</i> , 2014, 9, e97947.	2.5	16
29	Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.. <i>Journal of Biological Chemistry</i> , 2014, 289, 15154.	3.4	1
30	Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E278-E288.	3.5	31
31	Plasminogen Activator Inhibitor-1 Deficiency Ameliorates Insulin Resistance and Hyperlipidemia But Not Bone Loss in Obese Female Mice. <i>Endocrinology</i> , 2014, 155, 1708-1717.	2.8	29
32	The Roles of Urokinase-Type Plasminogen Activator in Leukocyte Infiltration and Inflammatory Responses in Mice Corneas Treated With Lipopolysaccharide. , 2014, 55, 5338.		17
33	Enhanced pre-operative thrombolytic status is associated with the incidence of deep venous thrombosis in patients undergoing total knee arthroplasty. <i>Thrombosis Journal</i> , 2014, 12, 11.	2.1	1
34	α 2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction. <i>Scientific Reports</i> , 2014, 4, 5967.	3.3	19
35	Plasminogen Activator Inhibitor-1 Is Involved in Streptozotocin-Induced Bone Loss in Female Mice. <i>Diabetes</i> , 2013, 62, 3170-3179.	0.6	46
36	Alpha2 β 1-Antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F ₂ α synthesis through adipose triglyceride lipase/calcium α -independent phospholipase A ₂ . <i>Arthritis and Rheumatism</i> , 2013, 65, 492-502.	6.7	31

#	ARTICLE	IF	CITATIONS
37	Lack of both α 2-antiplasmin and plasminogen activator inhibitor type-1 induces high IgE production. <i>Life Sciences</i> , 2013, 93, 89-95.	4.3	9
38	Enzamin ameliorates adipose tissue inflammation with impaired adipocytokine expression and insulin resistance in db/db mice. <i>Journal of Nutritional Science</i> , 2013, 2, e37.	1.9	4
39	Involvement of α 2-antiplasmin in dendritic growth of hippocampal neurons. <i>Journal of Neurochemistry</i> , 2013, 126, 58-69.	3.9	25
40	Tissue plasminogen activator deficiency promotes early phase regeneration in the olfactory epithelium after bulbectomy. <i>International Forum of Allergy and Rhinology</i> , 2013, 3, 458-467.	2.8	3
41	A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 935-942.	2.4	43
42	Plasminogen Plays a Crucial Role in Bone Repair. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1561-1574.	2.8	62
43	In Vivo Diagnostic Imaging Using Micro-CT: Sequential and Comparative Evaluation of Rodent Models for Hepatic/Brain Ischemia and Stroke. <i>PLoS ONE</i> , 2012, 7, e32342.	2.5	22
44	Mechanism of the experimental antithrombotic effect of some apple varieties involves enhanced endogenous thrombolytic activity. <i>Interventional Medicine & Applied Science</i> , 2012, 4, 115-124.	0.2	2
45	Involvement of Plasminogen Activator Inhibitor-1 in the Pathogenesis of Atopic Cataracts. , 2012, 53, 1846.		8
46	Urokinase-type plasminogen activator and plasminogen mediate activation of macrophage phagocytosis during liver repair in vivo. <i>Thrombosis and Haemostasis</i> , 2012, 107, 749-759.	3.4	16
47	Turning point on the development of research career. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2012, 23, 520-526.	0.1	0
48	Urokinase-type plasminogen activator contributes to heterogeneity of macrophages at the border of damaged site during liver repair in mice. <i>Thrombosis and Haemostasis</i> , 2011, 105, 892-900.	3.4	15
49	The Absence of Urokinase-type Plasminogen Activator Receptor Plays a Role in the Insulin-independent Glucose Metabolism. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 334-339.	1.9	3
50	Spatiotemporal differences in vascular permeability after ischaemic brain damage. <i>NeuroReport</i> , 2011, 22, 424-427.	1.2	3
51	Profibrinolytic effect of Enzamin, an extract of metabolic products from <i>Bacillus subtilis</i> AK and <i>Lactobacillus</i> . <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 195-200.	2.1	6
52	Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus. <i>Cell and Tissue Research</i> , 2011, 343, 303-317.	2.9	25
53	Trial of integrated laboratory practice. <i>American Journal of Physiology - Advances in Physiology Education</i> , 2011, 35, 237-240.	1.6	7
54	Plasminogen/Plasmin Modulates Bone Metabolism by Regulating the Osteoblast and Osteoclast Function. <i>Journal of Biological Chemistry</i> , 2011, 286, 8952-8960.	3.4	45

#	ARTICLE	IF	CITATIONS
55	Systemic transplantation of embryonic stem cells accelerates brain lesion decrease and angiogenesis. <i>NeuroReport</i> , 2010, 21, 575-579.	1.2	26
56	Enhancement of fibrinolytic activity in vascular endothelial cells by heterologous expression of adenine nucleotide translocase-1. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 272-278.	1.0	0
57	Initial brain lesion size affects the extent of subsequent pathophysiological responses. <i>Brain Research</i> , 2010, 1322, 109-117.	2.2	19
58	Tissue plasminogen activator and plasminogen are critical for osmotic homeostasis by regulating vasopressin secretion. <i>Journal of Neuroscience Research</i> , 2010, 88, 1995-2006.	2.9	30
59	Determination of a factor VIII-interactive region within plasmin responsible for plasmin-catalysed activation and inactivation of factor VIII(a). <i>Thrombosis and Haemostasis</i> , 2010, 104, 105-117.	3.4	5
60	Urokinase-type plasminogen activator receptor is associated with the development of adipose tissue. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1124-1132.	3.4	20
61	Roles of fibrinolytic system components in the nervous system. <i>Pathophysiology</i> , 2010, 17, 141-147.	2.2	5
62	Pathophysiology in Japan. <i>Pathophysiology</i> , 2010, 17, 71.	2.2	0
63	Role of plasminogen in macrophage accumulation during liver repair. <i>Thrombosis Research</i> , 2010, 125, e214-e221.	1.7	15
64	Î±2-Antiplasmin Is Associated with the Progression of Fibrosis. <i>American Journal of Pathology</i> , 2010, 176, 238-245.	3.8	25
65	The Absence of uPAR Is Associated with the Progression of Dermal Fibrosis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2792-2797.	0.7	44
66	Role of Fibrinolysis in Hepatic Regeneration. , 2008, , 336-347.		1
67	Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke. <i>Neuroscience Letters</i> , 2008, 432, 46-49.	2.1	25
68	Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxemia. <i>Thrombosis Research</i> , 2008, 122, 91-97.	1.7	14
69	The absence of uPAR attenuates insulin-induced vascular smooth muscle cell migration and proliferation. <i>Thrombosis Research</i> , 2008, 123, 336-341.	1.7	14
70	Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin IIâ€‘Mediated Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1257-1262.	2.4	22
71	Binding of plasminogen to hepatocytes isolated from injured mice liver and nonparenchymal cell-dependent proliferation of hepatocytes. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 503-511.	1.0	8
72	VEGF-B inhibits apoptosis via VEGFR-1â€‘mediated suppression of the expression of BH3-only protein genes in mice and rats. <i>Journal of Clinical Investigation</i> , 2008, 118, 913-23.	8.2	144

#	ARTICLE	IF	CITATIONS
73	Liver regeneration and fibrinolytic system. Japanese Journal of Thrombosis and Hemostasis, 2008, 19, 216-225.	0.1	0
74	c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells. Cardiovascular Research, 2007, 75, 186-194.	3.8	17
75	Effect of staphylokinase-derived nonadecapeptide on the activation of plasminogen. Thrombosis and Haemostasis, 2007, 97, 795-802.	3.4	6
76	Mesenchymal progenitor cells in adult human dental pulp and their ability to form bone when transplanted into immunocompromised mice. Cell Biology International, 2007, 31, 1191-1197.	3.0	81
77	Plasmin decreases the BH3-only protein BimEL via the ERK1/2 signaling pathway in hepatocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 718-727.	4.1	11
78	Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.. Blood, 2007, 110, 1759-1759.	1.4	1
79	Development of New Fibrinolytic Agents. Current Pharmaceutical Design, 2006, 12, 849-857.	1.9	25
80	Protection of Plasminogen Activator Inhibitor-1-Deficient Mice from Nasal Allergy. Journal of Immunology, 2005, 174, 8135-8143.	0.8	43
81	Tissue Type Plasminogen Activator Facilitates NMDA-Receptor-Mediated Retinal Apoptosis through an Independent Fibrinolytic Cascade. , 2005, 46, 1504.		31
82	Endogenous tissue type plasminogen activator facilitates NMDA-induced retinal damage. Toxicology and Applied Pharmacology, 2004, 200, 48-53.	2.8	14
83	Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells. Thrombosis Research, 2004, 113, 41-49.	1.7	3
84	The regulation of liver regeneration by the plasmin/ α 2-antiplasmin system. Journal of Hepatology, 2004, 40, 110-116.	3.7	31
85	Effect of clinical clerkship on students' attitudes toward medical learning in Japan: a case study at Kinki University School of Medicine. Pathophysiology, 2003, 9, 111-113.	2.2	2
86	Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. Pathophysiology, 2003, 9, 103-109.	2.2	9
87	Cellular density regulation of plasminogen gene expression in mouse hepatocytes. Life Sciences, 2003, 72, 1695-1704.	4.3	6
88	Lack of α 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. Blood, 2003, 102, 3621-3628.	1.4	18
89	Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thrombosis and Haemostasis, 2003, 89, 820-825.	3.4	11
90	Influence of Low- and High-Molecular-Weight Plasminogen Activators on the Onset of Labor and on the Hemostatic System. Seminars in Thrombosis and Hemostasis, 2002, 28, 529-532.	2.7	0

#	ARTICLE	IF	CITATIONS
91	Inhibitors of Fibrinolytic Components Play Different Roles in the Formation and Removal of Arterial Thrombus in Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 39, 278-286.	1.9	14
92	Lack of α 2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. <i>Blood</i> , 2002, 100, 2487-2493.	1.4	39
93	Loss of placental growth factor protects mice against vascular permeability in pathological conditions. <i>Biochemical and Biophysical Research Communications</i> , 2002, 295, 428-434.	2.1	81
94	Plasmin Generation Plays different Roles in the Formation and Removal of Arterial and Venous Thrombus in Mice. <i>Thrombosis and Haemostasis</i> , 2002, 87, 98-104.	3.4	25
95	Function of Tissue-type Plasminogen Activator Releaser on Vascular Endothelial Cells and Thrombolysis In Vivo. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1069-1074.	3.4	13
96	Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 205-211.	2.1	8
97	Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. <i>Thrombosis and Haemostasis</i> , 2002, 87, 98-104.	3.4	13
98	Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1069-74.	3.4	2
99	Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. <i>Hepatology</i> , 2001, 33, 569-576.	7.3	100
100	The interaction between components of the fibrinolytic system and GPIIb/IIIa of platelets thrombus formation in mice. <i>British Journal of Pharmacology</i> , 2000, 131, 858-864.	5.4	4
101	Roles of urokinase type plasminogen activator in a brain stab wound. <i>Brain Research</i> , 2000, 887, 187-190.	2.2	21
102	Lack of tPA Significantly Affects Antithrombotic Therapy by a GPIIb/IIIa Antagonist, but not by a Thrombin Inhibitor in Mice. <i>Thrombosis and Haemostasis</i> , 2000, 83, 605-609.	3.4	12
103	Binding of mutant tissue-type plasminogen activators to human endothelial cells and their extracellular matrix. <i>Life Sciences</i> , 2000, 66, 2473-2487.	4.3	1
104	Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines. <i>Clinica Chimica Acta</i> , 2000, 296, 17-33.	1.1	17
105	Antithrombotic Regulation in Human Endothelial Cells by Fibrinolytic Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 033-038.	2.7	14
106	tPA, but not uPA, Significantly Affects Antithrombotic Therapy by a Glycoprotein IIb/IIIa Antagonist, but not by a Factor Xa Inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, 770-775.	1.9	8
107	Biocompatible Block Copolymers Composed of Polydimethylsiloxane and Poly[(2-methacryloyloxy)ethyl phosphorylcholine] Segments. <i>Polymer Journal</i> , 1999, 31, 883-886.	2.7	23
108	Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice. <i>Neuroscience Letters</i> , 1999, 266, 220-222.	2.1	4

#	ARTICLE	IF	CITATIONS
109	Differential Role of Components of the Fibrinolytic System in the Formation and Removal of Thrombus Induced by Endothelial Injury. <i>Thrombosis and Haemostasis</i> , 1999, 81, 601-604.	3.4	64
110	Co-localization of Urokinase and its Receptor on Established Human Umbilical Vein Endothelial Cell.. <i>Cell Structure and Function</i> , 1999, 24, 71-78.	1.1	5
111	Grafting of vinyl monomers on the surface of a poly(ethylene terephthalate) film using Ar plasma-post polymerization technique to increase biocompatibility. <i>Macromolecular Chemistry and Physics</i> , 1998, 199, 1201-1208.	2.2	42
112	Fibrinolytic factors, matrix metalloprotease-1, and tissue inhibitor of metalloproteinase-1 in gastric carcinoma. <i>Pathophysiology</i> , 1998, 5, 99-104.	2.2	1
113	Analysis of Tissue-Type Plasminogen Activator Receptor (t-PAR) in Human Endothelial Cells. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 269-273.	2.7	6
114	Transcriptional Regulation of Urokinase-type Plasminogen Activator Receptor by Cyclic AMP in PL-21 Human Myeloid Leukemia Cells: Comparison with the Regulation by Phorbol Myristate Acetate. <i>Thrombosis and Haemostasis</i> , 1998, 79, 574-578.	3.4	10
115	Surface Modified Poly(methyl methacrylate) Microspheres with the O-Methacryloyl-L-serine Moiety. <i>Chemistry Letters</i> , 1997, 26, 863-864.	1.3	9
116	Enhancement of tissue-type plasminogen activator (t-PA) activity by purified t-PA receptor expressed in human endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1356, 111-120.	4.1	18
117	The Role of the Pericellular Fibrinolytic System in Angiogenesis.. <i>The Japanese Journal of Physiology</i> , 1997, 47, 161-171.	0.9	20
118	New Aspects of Fibrinolytic Proteins in Brain Development.. <i>Cell Structure and Function</i> , 1997, 22, 225-229.	1.1	3
119	Effects of lipopolysaccharide on the expression of fibrinolytic factors in an established cell line from human endothelial cells. <i>Life Sciences</i> , 1996, 59, 85-96.	4.3	13
120	Stabilization of plasmin by lysine derivatives. <i>Clinica Chimica Acta</i> , 1996, 245, 7-18.	1.1	267
121	Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line. <i>Clinica Chimica Acta</i> , 1996, 253, 37-50.	1.1	5
122	Effects of fibrin and α_2 -antiplasmin on plasminogen activation by staphylokinase. , 1996, 53, 151-157.		15
123	Effect of Heat Shock on the Expression of Urokinase-Type Plasminogen Activator Receptor in Human Umbilical Vein Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 1996, 75, 352-358.	3.4	10
124	Comparative Studies of Thrombolysis with Single-Chain and Two-Chain Recombinant Tissue-Type Plasminogen Activators in Canine Coronary Thrombosis. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 28, 571-575.	1.9	1
125	FIBRINOLYTIC ACTIVITY IN LIVER TISSUES OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, S275-S276.	1.9	3
126	Effect of cyclic AMP on urokinase-type plasminogen activator receptor and fibrinolytic factors in a human osteoblast-like cell line. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1266, 50-56.	4.1	8

#	ARTICLE	IF	CITATIONS
127	Identification of Urokinase-type Plasminogen Activator Receptor in Human Endothelial Cells and its Modulation by Phorbol Myristate Acetate.. Cell Structure and Function, 1995, 20, 429-437.	1.1	7
128	Effect of bone resorbing factors on u-PA and its specific receptor in osteosarcoma cell line. Clinica Chimica Acta, 1993, 223, 129-142.	1.1	8
129	Regulation of scu-PA secretion and u-PA Receptor Expression in Osteoblast-like Cells.. Cell Structure and Function, 1993, 18, 355-362.	1.1	2
130	Analysis of binding protein for tissue-type plasminogen activator in human endothelial cells. Biochemical and Biophysical Research Communications, 1992, 187, 956-962.	2.1	19
131	Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. Journal of Pathology, 1992, 166, 289-295.	4.5	16
132	On the molecular interactions between plasminogen-staphylokinase, α_2 -antiplasmin-formula> and fibrin. BBA - Proteins and Proteomics, 1992, 1118, 144-148.	2.1	49
133	Plasminogen activator inhibitor 1 in human carcinoma tissues. International Journal of Cancer, 1991, 48, 481-484.	5.1	35
134	Plasminogen Activator Inhibitor in Stomach and Colorectal Carcinomas. Seminars in Thrombosis and Hemostasis, 1991, 17, 276-279.	2.7	12
135	Activity of tissue plasminogen activator and plasminogen activator inhibitor in noninsulin-dependent diabetes mellitus. The Journal of Diabetic Complications, 1990, 4, 119-121.	0.2	9
136	Absence of t-PA in spontaneous metastatic lesions induced by a newly established cell line. Thrombosis Research, 1989, 53, 395-400.	1.7	2
137	Mechanism of fibrin-specific fibrinolysis by staphylokinase: Participation of α_2 -plasmin inhibitor. Biochemical and Biophysical Research Communications, 1989, 162, 830-837.	2.1	57
138	Determination of the biological activity of antithrombin III related antigen in urine. Clinica Chimica Acta, 1989, 180, 79-86.	1.1	0
139	Secretion of Plasminogen Activator in Response to Follicleâ€stimulating Hormone in Culture Medium of Human Testicular Cells from Biopsy Specimens. Journal of Andrology, 1989, 10, 283-288.	2.0	2
140	Production and characterization of single-chain tissue-type plasminogen activator produced by an established cell line from human uterine muscle.. Cell Structure and Function, 1989, 14, 45-60.	1.1	14
141	Effect of monensin on secretion of t-PA from melanoma (Bowes).. Cell Structure and Function, 1989, 14, 673-684.	1.1	2
142	Characterization of plasminogen activator produced by an established cell line from human ovary. Journal of Cellular Physiology, 1988, 134, 253-260.	4.1	12
143	Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thrombosis Research, 1988, 52, 165-171.	1.7	40
144	High-performance chromatographic method for the purification of tissue-type plasminogen activator. Journal of Chromatography A, 1986, 369, 391-397.	3.7	13

#	ARTICLE	IF	CITATIONS
145	Properties of granuloma associated plasminogen activator (PA) and its relation to macrophage PA.. Blood & Vessel, 1985, 16, 220-222.	0.0	0
146	Monoclonal antibody to human tissue plasminogen activator. Thrombosis Research, 1984, 36, 517-526.	1.7	16
147	ANALYSIS OF FLUID IN CAPSULES IMPLANTED INTO DOG BRAIN. The Japanese Journal of Physiology, 1974, 24, 59-71.	0.9	4